Mode
Text Size
Log in / Sign up
N/A N=37 Randomized Single-blind Treatment

A Unified Treatment for Anxiety Disorders

Emotional Disorders · Anxiety Disorders

Enrolled (actual)
37
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcome: Primary: Anxiety Disorders Interview Schedule for DSM-IV — 5.23; 5.09; 3.18; 5.14 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Boston University Charles River Campus
Primary completion
Nov 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Anxiety Disorders Interview Schedule for DSM-IV
5.23; 5.09; 3.18; 5.14
SECONDARY
Structured Interview Guide for the Hamilton Anxiety Rating Scale
16.15; 14.36; 7.39; 13.08
SECONDARY
Structured Interview Guide for the Hamilton Depression Rating Scale
10.35; 10.09; 5.49; 7.85
SECONDARY
Positive and Negative Affect Scale
28.81; 28.00; 32.84; 27.17; 26.62; 24.36
SECONDARY
Beck Depression Inventory - II
11.96; 11.73; 4.21; 11.45
SECONDARY
Beck Anxiety Inventory
19.08; 16.91; 8.27; 12.22
SECONDARY
Work and Social Adjustment Scale
16.04; 16.46; 7.62; 13.14
SECONDARY
Panic Disorder Severity Scale - Self Report Version
7.65; 7.09; 2.77; 6.20
SECONDARY
Penn State Worry Questionnaire
62.27; 62.55; 49.18; 60.30
SECONDARY
Social Interaction Anxiety Scale
28.19; 38.18; 23.32; 37.60
SECONDARY
Quality of Life Inventory
35.46; 32.45; 46.73; 34.67
SECONDARY
Yale-Brown Obsessive Compulsive Scale
8.81; 7.18; 6.09; 8.65
SECONDARY
Emotion Regulation Questionnaire - 2
55.40; 60.36; 59.95; 60.00
SECONDARY
BIS/BAS Scales (Carver & White, 1994)
24.15; 24.45; 22.32; 23.60; 38.09; 35.18
SECONDARY
Affective Control Scale
140.92; 141.00; 106.36; 141.60
SECONDARY
Anxiety Sensitivity Index
29.62; 29.27; 19.36; 25.50
SECONDARY
The Thought-Action Fusion Scale (Shafran et al., 1996)
13.46; 16.82; 11.43; 16.90
SECONDARY
Intolerance of Uncertainty Scale (IUS)
40.38; 39.27; 27.77; 40.25
SECONDARY
The Trait Meta-Mood Scale (TMMS; Salovey et al., 1995)
76.83; 76.50; 50.83; 51.30; 39.43; 37.40

Summary

The purpose of this study is to develop a new psychological therapy for a variety of different types of emotional disorders. The study will compare symptoms and functioning of clients who receive the treatment with those who do not, and will include a number of assessments before, during, and after treatment. We predict that patients receiving active treatment will show improved functioning relative to wait-list control.

Eligibility Criteria

Inclusion Criteria

  • Primary Diagnosis of a DSM-IV Anxiety Disorder

Exclusion Criteria

  • Previous treatment with cognitive-behavioral therapy
  • Receiving concurrent psychological treatments during study
  • If on psychotropic medicine, requirement for stable dose for at least three months before treatment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00586001). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search